Investors
Oxurion/Investors/News/NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY …

NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL

26 Jan 2018Regulated informationTransparency/Denominator
View original on Oxurion.com

This document constitutes regulated information in the sense of the Royal Decree of 14 November 2007 and/or the Law of 2 August 2002. For the full press release, download the PDF document(s) above.


Back to news